SCHEMBL3931343

SCHEMBL3931343

COc1ccc(-c2cc3ncnc(N(C)c4ccc5c(c4)OCO5)c3s2)cc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17B O94768 1/20 0.49
CLK4 Q9HAZ1 7/20 0.41
ALDH1A1 P00352 2/20 0.41
LMNA P02545 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
TSHR P16473 2/20 0.41
CYP2C19 P33261 2/20 0.41
HIF1A Q16665 2/20 0.41
HSD17B10 Q99714 2/20 0.41
MAPK1 P28482 1/20 0.41
DYRK1A Q13627 6/20 0.39
DYRK1B Q9Y463 6/20 0.39
CLK1 P49759 5/20 0.39
CLK2 P49760 5/20 0.39
CLK3 P49761 4/20 0.39
GSK3B P49841 1/20 0.38
HSD17B2 P37059 1/20 0.37
PI4KB Q9UBF8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4071089 0.90 CLK4 (0.45) STK17BCLK4ALDH1A1LMNACYP1A2
SCHEMBL3930446 0.88 CLK4 (0.43) STK17BCLK4ALDH1A1LMNACYP1A2
SCHEMBL4068339 0.87 LRRK2 (0.39) STK17BCLK4ALDH1A1LMNACYP1A2
SCHEMBL4064308 0.87 CLK4 (0.43) STK17BCLK4ALDH1A1LMNACYP1A2
SCHEMBL3928353 0.86 EGFR (0.43) CLK4ALDH1A1LMNACYP1A2CYP3A4
SCHEMBL4064459 0.86 KMT2A (0.52) CLK4ALDH1A1LMNACYP1A2CYP3A4
SCHEMBL4068416 0.86 TYK2 (0.49) CLK4ALDH1A1LMNACYP1A2CYP3A4
SCHEMBL4074732 0.85 CLK4 (0.43) STK17BCLK4ALDH1A1LMNACYP1A2
SCHEMBL3927054 0.85 HSD17B2 (0.39) STK17BCLK4ALDH1A1LMNACYP1A2
SCHEMBL3927275 0.84 PDE5A (0.42) CLK4ALDH1A1LMNACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP claimed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
WO-2009007422-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-15 WO disclosed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 STK17B 1911/4885CLK4 4484/4885ALDH1A1 1167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.